207 related articles for article (PubMed ID: 28263937)
1. Identifying Drug-Drug Interactions by Data Mining: A Pilot Study of Warfarin-Associated Drug Interactions.
Hansen PW; Clemmensen L; Sehested TS; Fosbøl EL; Torp-Pedersen C; Køber L; Gislason GH; Andersson C
Circ Cardiovasc Qual Outcomes; 2016 Nov; 9(6):621-628. PubMed ID: 28263937
[TBL] [Abstract][Full Text] [Related]
2. Suboptimal Anticoagulant Management in Japanese Patients with Nonvalvular Atrial Fibrillation Receiving Warfarin for Stroke Prevention.
Hirano T; Kaneko H; Mishina S; Wang F; Morita S
J Stroke Cerebrovasc Dis; 2017 Oct; 26(10):2102-2110. PubMed ID: 28532651
[TBL] [Abstract][Full Text] [Related]
3. Anticoagulation control and cost of monitoring of older patients on chronic warfarin therapy in three settings in North East England.
Abohelaika S; Kamali F; Avery P; Robinson B; Kesteven P; Wynne H
Age Ageing; 2014 Sep; 43(5):708-11. PubMed ID: 24947831
[TBL] [Abstract][Full Text] [Related]
4. D-Dimer versus International Normalized Ratio of Prothrombin Time in Ischemic Stroke Patients Treated with Sufficient Warfarin.
Yamamoto R; Nakae Y; Tanaka F; Johkura K
J Stroke Cerebrovasc Dis; 2016 Jul; 25(7):1781-1785. PubMed ID: 27103270
[TBL] [Abstract][Full Text] [Related]
5. Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation.
Lind M; Fahlén M; Kosiborod M; Eliasson B; Odén A
Thromb Res; 2012 Jan; 129(1):32-5. PubMed ID: 21851969
[TBL] [Abstract][Full Text] [Related]
6. Design and rationale for the WARFA trial: a randomized controlled cross-over trial testing the therapeutic equivalence of branded and generic warfarin in atrial fibrillation patients in Brazil.
Freitas CG; Walsh M; Atallah ÁN
BMC Cardiovasc Disord; 2017 Jun; 17(1):148. PubMed ID: 28592234
[TBL] [Abstract][Full Text] [Related]
7. Clinical Prediction Model for Time in Therapeutic Range While on Warfarin in Newly Diagnosed Atrial Fibrillation.
Williams BA; Evans MA; Honushefsky AM; Berger PB
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29025746
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the impact of warfarin time in therapeutic range on outcomes of patients with atrial fibrillation in Turkey: perspectives from the observational, prospective WATER Registry.
Turk UO; Tuncer E; Alioglu E; Yuksel K; Pekel N; Ozpelit E; Vuran O; Tengiz I
Cardiol J; 2015; 22(5):567-75. PubMed ID: 26100825
[TBL] [Abstract][Full Text] [Related]
9. Causes of Ischemic Stroke in Patients with Non-Valvular Atrial Fibrillation.
Nakamura A; Kuroda J; Ago T; Hata J; Matsuo R; Arakawa S; Kuwashiro T; Yasaka M; Okada Y; Kitazono T; Kamouchi M;
Cerebrovasc Dis; 2016; 42(3-4):196-204. PubMed ID: 27111222
[TBL] [Abstract][Full Text] [Related]
10. Warfarin prescription in patients with nonvalvular atrial fibrillation and one non-gender-related risk factor (CHA
Denas G; Zoppellaro G; Padayattil Jose S; Antonucci E; Marongiu F; Poli D; Testa S; Tripodi A; Palareti G; Pengo V
Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29078033
[TBL] [Abstract][Full Text] [Related]
11. Time in Therapeutic Range and Outcomes After Warfarin Initiation in Newly Diagnosed Atrial Fibrillation Patients With Renal Dysfunction.
Szummer K; Gasparini A; Eliasson S; Ärnlöv J; Qureshi AR; Bárány P; Evans M; Friberg L; Carrero JJ
J Am Heart Assoc; 2017 Mar; 6(3):. PubMed ID: 28249846
[TBL] [Abstract][Full Text] [Related]
12. Long-term PT-INR levels and the clinical events in the patients with non-valvular atrial fibrillation: a special reference to low-intensity warfarin therapy.
Takarada K; Sato M; Goto M; Saito A; Ikeda Y; Fujita S; Fuse K; Takahashi M; Oguro T; Matsushita H; Kitazawa H; Okabe M; Abe H; Toba K; Yamashina A; Aizawa Y
J Cardiol; 2014 Aug; 64(2):127-32. PubMed ID: 24440439
[TBL] [Abstract][Full Text] [Related]
13. [Effects of Tramadol Coadministration on Prothrombin Time-International Normalized Ratio in Patients Receiving Warfarin].
Hosono T; Kondo A; Kambayashi Y; Homma M
Yakugaku Zasshi; 2017; 137(8):999-1003. PubMed ID: 28768953
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of an initiation protocol of 4 mg of warfarin for atrial fibrillation in the outpatient setting.
Sridhar VS; Leung P; Seymour N; Nagge J
Can Fam Physician; 2014 Nov; 60(11):e535-40. PubMed ID: 25551135
[TBL] [Abstract][Full Text] [Related]
15. Influence of the concomitant use of heparin on the effects of warfarin during catheter ablation for atrial fibrillation.
Inada K; Matsuo S; Tokutake K; Yokoyama K; Hioki M; Narui R; Ito K; Tanigawa S; Yamashita S; Tokuda M; Shibayama K; Miyanaga S; Sugimoto K; Yoshimura M; Yamane T
Heart Vessels; 2016 Mar; 31(3):397-401. PubMed ID: 25471944
[TBL] [Abstract][Full Text] [Related]
16. Contribution of rivaroxaban to the international normalized ratio when switching to warfarin for anticoagulation as determined by simulation studies.
Siegmund HU; Burghaus R; Kubitza D; Coboeken K
Br J Clin Pharmacol; 2015 Jun; 79(6):959-66. PubMed ID: 25510952
[TBL] [Abstract][Full Text] [Related]
17. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation.
Björck F; Renlund H; Lip GY; Wester P; Svensson PJ; Själander A
JAMA Cardiol; 2016 May; 1(2):172-80. PubMed ID: 27437888
[TBL] [Abstract][Full Text] [Related]
18. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.
Agarwal S; Bennett D; Smith DJ
Am J Cardiovasc Drugs; 2010; 10(1):37-48. PubMed ID: 20104933
[TBL] [Abstract][Full Text] [Related]
19. Effect of therapeutic INR on activated clotting times, heparin dosage, and bleeding risk during ablation of atrial fibrillation.
Gautam S; John RM; Stevenson WG; Jain R; Epstein LM; Tedrow U; Koplan BA; McClennen S; Michaud GF
J Cardiovasc Electrophysiol; 2011 Mar; 22(3):248-54. PubMed ID: 20812929
[TBL] [Abstract][Full Text] [Related]
20. Multivitamin supplement interaction with warfarin therapy.
Ducharlet KN; Katz B; Leung S
Australas J Ageing; 2011 Mar; 30(1):41-2. PubMed ID: 21395940
[No Abstract] [Full Text] [Related]
[Next] [New Search]
